medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-520Research ArticleСтатьиДиагностика и лечение резистентной артериальной гипертонииDiagnosis and treatment of resistant hypertensionГринштейнЮ. И.GrinshteinYu. I.noemail@neicon.ruШабалинВ. В.ShabalinV. V.noemail@neicon.ruФГБОУ ВО «Красноярский государственный медицинский университет имени проф. В. Ф. Войно-Ясенецкого» Минздрава РоссииРоссияKrasnoyarsk State Medical University n.a. prof. V. F. Voino-YasenetskyRussian Federation20182801201813Артериальная гипертензия3742Copyright © Гринштейн Ю.И., Шабалин В.В., 20182018Гринштейн Ю.И., Шабалин В.В.Grinshtein Y.I., Shabalin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/520

Резистентная гипертония (РГ) представляет собой артериальную гипертонию, не контролируемую на комбинации оптимальных доз трех гипотензивных препаратов, одним из которых является диуретик, при условии изменения образа жизни. В обзорной статье обсуждаются современные подходы к классификации РГ, алгоритму диагностики, дифференциальной диагностики и лечению. Особое внимание уделяется необходимости суточного мониторирования артериального давления для выделения специфических форм РГ и псевдорезистентности. Представлены традиционные и новые подходы к оптимальной медикаментозной и интервенционной терапии. Подробно освещены спорные моменты применения новых интервенционных методик коррекции РГ в реальной клинической практике.

Resistant hypertension (RH) can be defined as arterial hypertension not controlled by the use of three antihypertensive medicines (one being a diuretic) at optimal doses provided changed lifestyle. The present review summarizes the modern approaches to RH classification, diagnostic algorithm, differential diagnoses, and treatment. Special attention is paid to ambulatory blood pressure monitoring as essential tool for distinguishing specific hypertension types and pseudoresistance verification. Both traditional and new options of medicinal and interventional therapies are presented. Controversial issues of interventional techniques for RH correction are also discussed.

резистентная гипертониядиагностикафармакотерапияренальная денервацияresistant hypertensiondiagnosispharmacotherapyrenal denervationReferencesde Oliveira C., Marmot M. G., Demakakos P., de Melo Mambrini J. V., Peixoto S. V., Viana S., Lima-Costa M.F. Mortality risk attributable to smoking, hypertension and diabetes among English and Brazilian older adults (The ELSA and Bambui cohort ageing studies) // Eur J Public Health.-2015.-Dec,14.-pii: ckv225.de Oliveira C., Marmot M. G., Demakakos P., de Melo Mambrini J. V., Peixoto S. V., Viana S., Lima-Costa M.F. Mortality risk attributable to smoking, hypertension and diabetes among English and Brazilian older adults (The ELSA and Bambui cohort ageing studies) // Eur J Public Health.-2015.-Dec,14.-pii: ckv225.European Guidelines On Cardiovascular Disease Prevention In Clinical Practice // Eur Hear J.-2016.- 37.- P. 2315-2381.European Guidelines On Cardiovascular Disease Prevention In Clinical Practice // Eur Hear J.-2016.- 37.- P. 2315-2381.Гринштейн Ю. И., Петрова М. М., Шабалин В. В. и др. Распространенность артериальной гипертонии в Красноярском крае по данным эпидемиологического исследования ЭССЕ-РФ// Артериальная гипертензия.- 2016.- Том 22, № 6.- С. 551-559.Гринштейн Ю. И., Петрова М. М., Шабалин В. В. и др. Распространенность артериальной гипертонии в Красноярском крае по данным эпидемиологического исследования ЭССЕ-РФ// Артериальная гипертензия.- 2016.- Том 22, № 6.- С. 551-559.Artyukhov I. P., Grinshtein Yu.I., Petrova M. M., Shabalin V. V., Ruf R. R. Prevalence of arterial hypertension in the Krasnoyarsk Krai (Siberia, Russia) // BMS Cardiovascular Disorders.-2017: 138 DOI 10.1186/ s12872-017-0559-5.Artyukhov I. P., Grinshtein Yu.I., Petrova M. M., Shabalin V. V., Ruf R. R. Prevalence of arterial hypertension in the Krasnoyarsk Krai (Siberia, Russia) // BMS Cardiovascular Disorders.-2017: 138 DOI 10.1186/ s12872-017-0559-5.Sim J. J., Bhandari S. K., Shi J. et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system // Mayo Clin. Proc.-2013.- Vol. 88, № 10.-Р. 1099-1107.Sim J. J., Bhandari S. K., Shi J. et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system // Mayo Clin. Proc.-2013.- Vol. 88, № 10.-Р. 1099-1107.Dudenbostel T. Resistant hypertension - complex mix of secondary causes and comorbidities // J. Hum. Hypertens. - 2014.- Vol. 28, № 1.- P. 1-2.Dudenbostel T. Resistant hypertension - complex mix of secondary causes and comorbidities // J. Hum. Hypertens. - 2014.- Vol. 28, № 1.- P. 1-2.Muxfeldt E.S., de Souza F., Margallo V.S. et al. Cardiovascular and renal complications in patients with resistant hypertension // Curr. Hypertens. Rep. - 2014.- Vol. 16, № 9.- P. 471.Muxfeldt E.S., de Souza F., Margallo V.S. et al. Cardiovascular and renal complications in patients with resistant hypertension // Curr. Hypertens. Rep. - 2014.- Vol. 16, № 9.- P. 471.de la Sierra A., Segura J., Banegas J. R. et al. Clinical features of8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring // Hypertension.- 2011.- Vol. 57, № 5. - Р. 898-902.de la Sierra A., Segura J., Banegas J. R. et al. Clinical features of8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring // Hypertension.- 2011.- Vol. 57, № 5. - Р. 898-902.Kleman M., Dhaniamraji S., Difillippo W. Prevalance and characteristics of pseudohypertension in patients with “resistant Hypertension” // J. Am. Soc. Hypertens.- 2013.- Vol. 7, № 6.- Р. 467-470.Kleman M., Dhaniamraji S., Difillippo W. Prevalance and characteristics of pseudohypertension in patients with “resistant Hypertension” // J. Am. Soc. Hypertens.- 2013.- Vol. 7, № 6.- Р. 467-470.Weber F., Anlauf M. Treatment resistant hypertension - investiagation and conservative management // Dtsch. Arztebl. Int. - 2014.- Vol. 111, № 25.- Р. 425-431.Weber F., Anlauf M. Treatment resistant hypertension - investiagation and conservative management // Dtsch. Arztebl. Int. - 2014.- Vol. 111, № 25.- Р. 425-431.Denolle T., Azizi M., Massart C. et al. Itraconazole: a new drug-related cause of hypertension // Ann. Cardiol. Angeiol. (Paris).- 2014.- Vol. 63, № 3.- Р. 213-215.Denolle T., Azizi M., Massart C. et al. Itraconazole: a new drug-related cause of hypertension // Ann. Cardiol. Angeiol. (Paris).- 2014.- Vol. 63, № 3.- Р. 213-215.Judd E., Calhone D.A. Apparent and true resistant hypertension: definition, prevalence and outcomes // J. Hum. Hyper-tens.- 2014.- Vol. 28, № 8.- Р. 463-468.Judd E., Calhone D.A. Apparent and true resistant hypertension: definition, prevalence and outcomes // J. Hum. Hyper-tens.- 2014.- Vol. 28, № 8.- Р. 463-468.Dudenbostel T. Resistant hypertension - complex mix of secondary causes and comorbidities // J. Hum. Hypertens.-2014.- Vol. 28, № 1.- P. 1-2.Dudenbostel T. Resistant hypertension - complex mix of secondary causes and comorbidities // J. Hum. Hypertens.-2014.- Vol. 28, № 1.- P. 1-2.Muxfeldt E. S., Margallo V.S., Guimaraes G. M. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension // Am. J. Hyper-tens. - 2014.- Vol. 27, № 8. - Р. 1069-1078.Muxfeldt E. S., Margallo V.S., Guimaraes G. M. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension // Am. J. Hyper-tens. - 2014.- Vol. 27, № 8. - Р. 1069-1078.Daugherty S. L., Powers J. D., Magid D.J. et al. Incidence and prognosis of resistant hypertension in hypertensive patients // Circulation.- 2012.- Vol. 125, № 13.- Р. 1635-1642.Daugherty S. L., Powers J. D., Magid D.J. et al. Incidence and prognosis of resistant hypertension in hypertensive patients // Circulation.- 2012.- Vol. 125, № 13.- Р. 1635-1642.Mancia G., Fagard R., Narkieicz K. et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of cardiology (ESC): e-mail: medalfavit@mail.ru Медицинский алфавит № 3 / 2018, том № 1 Артериальная гипертензия 2013.- Vol. 31, № 10.- Р. 1925-1938.Mancia G., Fagard R., Narkieicz K. et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of cardiology (ESC): e-mail: medalfavit@mail.ru Медицинский алфавит № 3 / 2018, том № 1 Артериальная гипертензия 2013.- Vol. 31, № 10.- Р. 1925-1938.Okawa T., Obara T., Ohkubo T. et al. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measure -ments: the J-HOME study // J. Hypertens.- 2006.- Vol. 24, № 9.- Р. 1737-1743.Okawa T., Obara T., Ohkubo T. et al. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measure -ments: the J-HOME study // J. Hypertens.- 2006.- Vol. 24, № 9.- Р. 1737-1743.Guichard J. L., Clark D. 3rd, Calhoun D. A. et al. Aldosterone receptor antagonists: current perspectives and therapies / / Vasc Health Risk Manag.-2013.- 9.- P. 321-31.Guichard J. L., Clark D. 3rd, Calhoun D. A. et al. Aldosterone receptor antagonists: current perspectives and therapies / / Vasc Health Risk Manag.-2013.- 9.- P. 321-31.Bobrie G., Frank M., Azizi M. et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistanthypertension: a prospective, randomized, open blinded endpoint study // J Hypertens. - 2012. - 30, № 8.- P. 1656-64.Bobrie G., Frank M., Azizi M. et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistanthypertension: a prospective, randomized, open blinded endpoint study // J Hypertens. - 2012. - 30, № 8.- P. 1656-64.Beaussier H., Boutouyrie, Bobrie G. et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistanthypertension and confirmed medication adherence // J Hypertens.- 2015.- 33, № 12.- P. 2526-33.Beaussier H., Boutouyrie, Bobrie G. et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistanthypertension and confirmed medication adherence // J Hypertens.- 2015.- 33, № 12.- P. 2526-33.Krum H., Schlaich M., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study // Lancet 2009. - 373 (9671).- P. 1275-81.Krum H., Schlaich M., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study // Lancet 2009. - 373 (9671).- P. 1275-81.Krum H., Schlaich M. P., Sobotka PA. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study // Lancet 2014.- 383 (9917).- P. 622-29.Krum H., Schlaich M. P., Sobotka PA. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study // Lancet 2014.- 383 (9917).- P. 622-29.Symplicity HTN-2 Investigators, Esler M. D., Krum H., Sobotka P. A. et al. Renal sympathetic denervation in patients with treat ment-resistanthypertension (The Symplicity HTN-2 Trial): a randomized controlled trial //Lancet 2010.-376 (9756).-P. 1903-09.Symplicity HTN-2 Investigators, Esler M. D., Krum H., Sobotka P. A. et al. Renal sympathetic denervation in patients with treat ment-resistanthypertension (The Symplicity HTN-2 Trial): a randomized controlled trial //Lancet 2010.-376 (9756).-P. 1903-09.Esler M.D, Bohm M., Sievert H. et al. Catheter-based renal denervation for the treatment of patients for the treatment of patients with treatment-resistant hypertension: 36 month results from the SIMPLICITY HTN-2 randomized clinical trial // Eur Heart J 2014. - 35 (26).- P. 1752-59.Esler M.D, Bohm M., Sievert H. et al. Catheter-based renal denervation for the treatment of patients for the treatment of patients with treatment-resistant hypertension: 36 month results from the SIMPLICITY HTN-2 randomized clinical trial // Eur Heart J 2014. - 35 (26).- P. 1752-59.Davis M. I., Filion K. B., Zhang D. et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis // J Am Coll Cardiol 2013.- 62 (3).- P. 231-41.Davis M. I., Filion K. B., Zhang D. et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis // J Am Coll Cardiol 2013.- 62 (3).- P. 231-41.Mahfoud F., Luscher T. F., Andersson B. et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation // Eur Heart J 2013.- 34 (28).- P. 2149-57.Mahfoud F., Luscher T. F., Andersson B. et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation // Eur Heart J 2013.- 34 (28).- P. 2149-57.Schlaich M. P., Schmieder R.E., Bakris G. et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension // J Am Coll Cardiol 2013.- 62 (22).- P. 2031-45.Schlaich M. P., Schmieder R.E., Bakris G. et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension // J Am Coll Cardiol 2013.- 62 (22).- P. 2031-45.Tsioufis C., Mahfould F., Mancia G. et al. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension // Eurointervention 2014.- 9 (9).- P. 1027-35.Tsioufis C., Mahfould F., Mancia G. et al. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension // Eurointervention 2014.- 9 (9).- P. 1027-35.Hering D., Esler M. D., Schlaich M. P. et al. Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation// EuroIntervention 2013.- 9 Suppl.- P. 127-35.Hering D., Esler M. D., Schlaich M. P. et al. Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation// EuroIntervention 2013.- 9 Suppl.- P. 127-35.Ziegler A. K., Franke J., Bertog S. C. Renal denervation in a patient with prior renal artery stenting // Catheter Cardiovasc inter/2013.- 81 (2).- P. 342-45.Ziegler A. K., Franke J., Bertog S. C. Renal denervation in a patient with prior renal artery stenting // Catheter Cardiovasc inter/2013.- 81 (2).- P. 342-45.Bhatt D. L., Kandzari D. E., O’Neill W.W. et al. A controlled trial of renal denervation for resistant hypertension // N Engl J Med 2014.- 370 (15).- P. 1393-401.Bhatt D. L., Kandzari D. E., O’Neill W.W. et al. A controlled trial of renal denervation for resistant hypertension // N Engl J Med 2014.- 370 (15).- P. 1393-401.Schlaich M. P., Esler M. D., Fink G. D. et al. Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation // Hypertension 2014.- 63 (3).- P. 426-32.Schlaich M. P., Esler M. D., Fink G. D. et al. Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation // Hypertension 2014.- 63 (3).- P. 426-32.Pathak A., Ewen S., Fajadet J. et al. From Symlicity HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? // EuroIntervention 2014.- 10 (1).-21-3.Pathak A., Ewen S., Fajadet J. et al. From Symlicity HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? // EuroIntervention 2014.- 10 (1).-21-3.Bohm M., Mahfoud F., Ukena C. et al. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry // Euro Intervention 2013.- 9 (4). - P. 484-92.Bohm M., Mahfoud F., Ukena C. et al. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry // Euro Intervention 2013.- 9 (4). - P. 484-92.Ariyanon W., Mao H., Adybelli 1. et al. Renal denervation: intractable hypertension and beyond // CardioRenalMed2014.-4 (1).-P. 22-3.Ariyanon W., Mao H., Adybelli 1. et al. Renal denervation: intractable hypertension and beyond // CardioRenalMed2014.-4 (1).-P. 22-3.Mendelsohn F. O. Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries // Clin Res Cardiol2014.- 103 (9).- P. 681-3.Mendelsohn F. O. Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries // Clin Res Cardiol2014.- 103 (9).- P. 681-3.Ott C., Mahfoud F., Schmid A. et al. Improvement of albuminuria after renal denervation // Int J Cardiol2014.- 173 (2).-P. 311-5.Ott C., Mahfoud F., Schmid A. et al. Improvement of albuminuria after renal denervation // Int J Cardiol2014.- 173 (2).-P. 311-5.Mahfoud F., Urban D., Teller D. et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial // Eur Heart J 2014. - 35 (33). - 2224-31.Mahfoud F., Urban D., Teller D. et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial // Eur Heart J 2014. - 35 (33). - 2224-31.

The authors declare that there are no conflicts of interest present.